| Abstrakt: |
A recent report from the N.N. Blokhin National Medical Research Center of Oncology discusses the treatment of relapsed Burkitt lymphoma using targeted drugs and stem cell transplantation. The research highlights the use of chemoimmunotherapy schemes in children with Burkitt lymphoma, achieving high long-term progression-free survival rates. However, the study also notes challenges in treating relapsed/refractory disease and the development of fatal complications post-transplantation. For more information, the full article can be accessed for free online. [Extracted from the article] |
